Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 1997

View Archived Issues

Angiotensin II antagonist effective for progression of diabetic nephropathy

FDA approves new labeling for Bristol-Myers Squibb's Pravachol

Agents for hyperandrogenic disorders from Merck & Co.

Delta-opioid agonists/antagonists described by SmithKline Beecham

Sanofi describes selective NK3 receptor antagonists

SKB reports neuronal calcium channel antagonists

NOS inhibitors disclosed by Searle

Novel immunosuppressants from Takeda

Radiosensitizing taxanes prepared by Florida State University

Compounds combining PAF antagonist and 5-ASA claimed by Uriach for IBD

Pharmacia & Upjohn discloses new antimicrobial agents

Pharmacokinetic data for pentafuside in rodents, monkeys and man

Pharmacia & Upjohn prepares potent and selective dopamine D4 antagonist

PD-170262: potent and selective PDGF TK inhibitor from Parke-Davis

DuPont Merck describes potent, orally bioavailable cyclic urea HIV protease inhibitor

Potent and selective iNOS inhibitor disclosed by Merck & Co.

SKB describes potent, selective IL-8beta receptor antagonists

Potent antitumor farnesyltransferase inhibitors discovered by Parke-Davis

MDL-101731 shows potent antiviral activity in vitro

Target of action of AR-177 elucidated

ESI Lederle launches generic acyclovir

Joint venture created to develop calanolide A as anti-HIV treatment

Neuraminidase inhibitors highlighted at antiviral conference

TheraTech reacquires marketing rights to testosterone patch product

Neurex's blood pressure treatment up for FDA advisory panel review in June